Loading stock data…
ARTV
$10.50-0.13 (-1.22%)
Pre-Market$11.33+0.83 (+7.90%)· Last close May 13
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Artiva Biotherapeutics, Inc. in the Healthcare sector is trading at $10.50. Wall Street consensus targets $31.20 (5 analysts), implying a +197.1% move over the next 12 months. The stock is currently 28% below its 52-week high of $14.53, remaining 117.4% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +197.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$10.50
Potential Downside
0%
Whystock Fair Value$10.50
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Mean target$31.20+197.1%
Range$18.00 – $40.00
Fundamentals
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-s...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$289.93M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-76.26%
Volume
Today's trading volume
423,606
Recent News
Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. By way of example, Artiva...
Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham
Artiva Biotherapeutics (NASDAQ:ARTV) is prioritizing rheumatoid arthritis (RA) as the lead indication for its non-genetically modified natural killer (NK) cell therapy platform, executives said during a discussion at the Needham Healthcare Conference. Speaking with Needham Senior Biotech Analyst Gil
Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update
Artiva Biotherapeutics (NASDAQ:ARTV) used a presentation and fireside chat at TD Cowen’s 46th Annual Healthcare Conference to outline its strategy in “deep B-cell depletion” for autoimmune disease, emphasizing rheumatoid arthritis (RA) as its lead indication and positioning its natural killer (NK) c
AtaiBeckley names Michael Faerm as finance chief
AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) announced that it has appointed Michael Faerm as chief financial officer, effective March 9, 2026, as the clinical-stage biotechnology company continues to advance its mental health treatment pipeline. According to the company, Faerm brings more than 25...
Undervalued Penny Stocks To Consider In January 2026
As the U.S. stock market begins a busy week of tech earnings and interest rate decisions, major indexes have seen gains following two weeks of losses, with gold reaching new heights amid geopolitical tensions. In this context, penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for investors willing to explore beyond the mainstream. Despite their vintage name, these stocks can provide significant potential for growth when backed by strong...